Trial Profile

Phase 3 randomized, double-blind, placebo-controlled trial of ANX005 in patients with Huntington's disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 09 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tanruprubart (Primary)
Indications Huntington's disease
Focus Registrational; Therapeutic Use

Most Recent Events

07 Aug 2023 According to a Annexon Biosciences media release, this trial now expected to be initiated in 2024 as the company prioritizes near-term pivotal development activities for GA.
08 Jan 2023 According to a Annexon Biosciences media release, this study is expected to initiate by the end of 2023.
06 Jan 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com